Browsing by Author "Martínez-Cordero, H"

Now showing 1 - 2 of 2

Primary plasma cell leukemia in Latin America: demographic, clinical, and prognostic characteristics. A study of GELAMM group
(Taylor and Francis Ltd., 2023) Peña, C; Riva, E; Schutz, N; Ramírez, A; Vásquez, J; del-Carpio, D; Seehaus, C; Ochoa, P; Vengoa, R; Duarte, P; Martínez-Cordero, H; Figueredo, Y; Ríos, RO; Ramírez, J; Bove, V; Roa, M; Russo, M; Espinoza, M; Rodriguez, G; Remaggi, G; Enciso, ME; Chandía, M; Fantl, D.
Primary plasma cell leukemia (pPCL) is an infrequent and aggressive plasma cell disorder. The prognosis is still very poor, and the optimal treatment remains to be established. A retrospective, multicentric, international observational study was performed. Patients from 9 countries of Latin America (LATAM) with a diagnosis of pPCL between 2012 and 2020 were included. 72 patients were included. Treatment was based on thalidomide in 15%, proteasome inhibitors (PI)-based triplets in 38% and chemotherapy plus IMIDs and/or PI in 29%. The mortality rate at 3 months was 30%. The median overall survival (OS) was 18 months. In the multivariate analysis, frontline PI-based triplets, chemotherapy plus IMIDs and/or PI therapy, and maintenance were independent factors of better OS. In conclusion, the OS of pPCL is still poor in LATAM, with high early mortality. PI triplets, chemotherapy plus IMIDs, and/or PI and maintenance therapy were associated with improved survival. © 2023 Informa UK Limited, trading as Taylor & Francis Group.
Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study
(Lippincott Williams and Wilkins, 2022) Riva E; Duarte PJ; Valcárcel, B; Remaggi, G; Murrieta, I; Corzo, A; Del Carpio, D; Peña, C; Vásquez, J; Bove, V; Teixeira, L; Fleury-Perini, G; Yantorno, S; Samánez, C; Lopresti, S; Altamirano, M; Villela, L; Ruiz-Arguelles, GJ; Ruiz-Delgado, GJ; Montaño, E; Verri, V; Zamora-Pérez, E; Pérez-Jacobo, F; Idrobo, H; Martínez-Cordero, H; Beltran, BE; Ramírez, J; Castillo, JJ; Malpica-Castillo, LE
PURPOSE: Waldenstrom Macroglobulinemia (WM) is a rare lymphoma with distinct clinical features, and data from Latin American patients are lacking. Therefore, we aim to investigate the clinical, therapy, and outcome patterns of WM in Latin America. METHODS: We retrospectively analyzed patients with WM diagnosed between 1991 and 2019 from 24 centers in seven Latin American countries. The study outcomes were overall survival (OS) and progression-free survival (PFS). RESULTS: We identified 159 cases (median age 67 years, male 62%). Most patients (95%) were symptomatic at diagnosis. The International Prognostic Scoring System for WM (IPSSWM) at diagnosis was available in 141 (89%) patients (high-risk 40%, intermediate-risk 37%, and low-risk 23%). Twenty-seven (17%) patients were tested for MYD88L265P, with 89% (n = 24 of 27) carrying the mutation. First-line and second-line therapies were administered to 142 (89%) and 53 (33%) patients, respectively. Chemoimmunotherapy was the most commonly used first-line (66%) and second-line (45%) approach